Treatment of Tubercular Endometritis

First-Line Treatment Regimen

The European Respiratory Society recommends a standard 6-month regimen consisting of daily isoniazid, rifampin, pyrazinamide, and ethambutol for the first 2 months, followed by daily isoniazid and rifampin for an additional 4 months, for optimal treatment efficacy 1
Daily dosage is strongly recommended over intermittent dosing for optimal treatment efficacy, as suggested by the European Respiratory Society 1

The American Thoracic Society recommends rifampin at a dosage of 10 mg/kg (up to 600 mg) daily 2
The American Thoracic Society recommends pyrazinamide at a dosage of 15-30 mg/kg daily 2
The Centers for Disease Control and Prevention recommends ethambutol at a dosage of 15-20 mg/kg daily 3

Patients should be taught to recognize symptoms of drug toxicity and report them promptly, as advised by the American Thoracic Society 2

The American Thoracic Society recommends adding a later-generation fluoroquinolone (levofloxacin or moxifloxacin) to a 6-month regimen of daily rifampin, ethambutol, and pyrazinamide for isoniazid-resistant TB 4
The World Health Organization recommends treatment with at least five effective TB medicines during the intensive phase for multidrug-resistant TB (MDR-TB) 5
The World Health Organization recommends a treatment regimen that includes drugs from Groups A, B, and C for MDR-TB 5
The European Respiratory Society recommends a treatment duration of 20 to 24 months for MDR-TB affecting the genital tract 5

The Centers for Disease Control and Prevention recommends modifying the standard regimen if treatment is necessary during pregnancy, and avoiding pyrazinamide due to insufficient teratogenicity data 3
The American Thoracic Society recommends extended treatment duration based on clinical response for patients with HIV co-infection, and careful management of drug interactions between antiretrovirals and anti-TB medications 2

Therapeutic drug monitoring may be necessary if poor response is suspected due to under-dosing or malabsorption, as suggested by the European Respiratory Society 1
Regular monitoring of liver function is essential, especially when using pyrazinamide, which can cause liver injury, as recommended by the Centers for Disease Control and Prevention 3